CliffBio
small molecule

VALGANCICLOVIR HYDROCHLORIDE

VALGANCICLOVIR HYDROCHLORIDE

Loss of exclusivity—loss of exclusivity
CompanyCipla →See this company's full patent-cliff portfolio

Drug detail

Brand nameVALGANCICLOVIR HYDROCHLORIDE
Active ingredientVALGANCICLOVIR HYDROCHLORIDE
StrengthEQ 450MG BASE
Dosage formTABLET
RouteORAL
ModalitySmall molecule
FDA approvalNovember 2018
Marketing statusDISCN

More from Cipla

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.

VALGANCICLOVIR HYDROCHLORIDE patent cliff — loss of exclusivity — | CliffBio